International Journal of Clinical Research

Objective To analyze the application effect of ELISA and nucleic acid amplification technology in blood screening of unpaid blood donors. Methods A total of 500 unpaid blood donors from May 2022 to May 2023 were selected as the subjects of this study. All subjects were tested by enzyme-linked immunosorbent assay (ELISA) to screen the blood samples for anti-HIV (human immunodeficiency virus antibody), anti-HCV (hepatitis C antibody), HBsAg (hepatitis B surface antigen), and then the qualified samples were further tested by nucleic acid amplification technology (NAT). The blood screening indexes of the subjects were finally observed. Results Among the 500 unpaid blood donors, there were 495 qualified blood donors, accounting for 99.00%, and 5 unqualified blood donors, accounting for 1.00%. After the combination of NAT detection technology, 490 of the 500 unpaid blood donors were found to be qualified, accounting for 98.00%, and 10 were unqualified, accounting for 2.00%. Among 490 subjects, 3 cases (0.61%) of HBV-DNA (Hepatitis B virus gene) were found positive by NAT test. Among 490 qualified blood donors, the positive rates of HBV-DNA were similar in different genders, with no statistical significance (P > 0.05). Conclusion The application of ELISA and NAT in blood screening of unpaid blood donors can sensitively detect infectious indicators and ensure the safety of blood transfusion.

Unpaid blood donation; Blood screening; Enzyme-linked immunosorbent assay; Nucleic acid amplification technique